Use of propargyl cysteine ​​in the preparation of drugs for treating hematological systemic tumors

A cysteine ​​and blood system technology, which is applied in the field of propargyl cysteine ​​in the preparation of drugs for treating hematological system tumors, can solve the problems such as no reports that propargyl cysteine ​​is anti-hematological tumor, etc. Inhibit cell cycle and promote apoptosis

Active Publication Date: 2021-05-04
FUDAN UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Studies have reported that SPRC protects cardiomyocytes from hypoxic damage and its role in the treatment of digestive system tumors and breast cancer, but so far, there has been no report on the anti-hematological system tumors of propargyl cysteine ​​(SPRC)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of propargyl cysteine ​​in the preparation of drugs for treating hematological systemic tumors
  • Use of propargyl cysteine ​​in the preparation of drugs for treating hematological systemic tumors
  • Use of propargyl cysteine ​​in the preparation of drugs for treating hematological systemic tumors

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Example 1 Cell Lines and Culture Mode

[0021] Human T lymphocytes (Jurkat) and lymphoma cells (Raji) cells (purchased from the cell bank of Shanghai Institute of Biological Sciences, China). Culture conditions: respectively culture Jurkat and Raji cells in RPMI 1640 containing 10% fetal bovine serum and 1-2% penicillin and streptomycin (100U / ml), and place the cells in a 5% CO2 incubator at 37°C.

Embodiment 2

[0022] Example 2 SPRC reduces cell viability experiment

[0023] 5*10-3 Jurkat and Raji cells were seeded in a 96-well plate with a volume of 200ul per well. Add SPRC to final concentrations of 0.16mg / ml, 0.8mg / ml, 1.6mg / ml and 3.2mg / ml respectively. After 48 hours of treatment, the cell viability was detected by the CCK-8 method, and the results were as follows: figure 1 As shown, the cell viability of 0.16mg / ml, 0.8mg / ml, 1.6mg / ml and 3.2mg / ml SPRC treatment groups were significantly lower than that of the normal control group, and SPRC can inhibit the growth of T lymphocytes and lymphoma cells. vitality.

Embodiment 3

[0024] Example 3 SPRC promotes cell apoptosis experiment

[0025] The Jurkat and Raji cells were seeded in culture dishes and treated with 0.8 and 1.6 mg / ml SPRC for 48 hours. Annexin I and PI stained cells were detected by flow cytometry and the results were as follows: figure 2 As shown, the results of flow cytometry showed that 0.8mg / ml SPRC can induce cell apoptosis, and 1.6mg / ml SPRC can significantly induce cell apoptosis.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of pharmacy and relates to the use of propargyl cysteine ​​(SPRC, S-propargyl-cysteine) in the preparation of drugs for treating hematological tumors. The present invention detects the effect of SPRC treatment on the cell viability of cancer cells through in vitro T lymphocyte and lymphoma cell culture experiments, and the results show that the SPRC can reduce the cell survival rate, promote cell apoptosis, and inhibit the S phase of the cell cycle block; can improve the cell viability of the apoptosis-promoting protein caspase3, the experimental results show that the propargyl cysteine ​​has an inhibitory effect on T lymphocytes and lymphoma cells, and the SPRC can be made into a therapeutic drug for the treatment of hematological malignancies.

Description

technical field [0001] The invention belongs to the field of pharmacy, and relates to a new drug application of propargyl cysteine ​​(SPRC, S-propargyl-cysteine), in particular to the use of propargyl cysteine ​​(SPRC) in the preparation of drugs for treating hematological system tumors use. Background technique [0002] The prior art discloses that allyl cysteine ​​(SAC, S-allycysteine) is a natural organic sulfur compound in garlic, and is the main active ingredient in mature garlic extract (Aged garlic extract), which is obtained by S-alk (en ) Degradation of ylcysteine ​​sulfoxides (ACSs). It has been reported in the literature that this compound has antitumor, antibacterial and antifungal properties. [0003] According to research reports, propargyl cysteine ​​(SPRC, S-propargyl-cysteine) is similar in structure to SAC (S-allycysteine) and has the same cysteine ​​structure. Studies have reported that SPRC protects cardiomyocytes from hypoxic damage and its role in th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/198A61P35/02
CPCA61K31/198
Inventor 朱依谆茅以诚马蓓蕾
Owner FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap